Diffuse large B cell lymphoma (patient information)

Jump to navigation Jump to search


Overview

Diffuse large B cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Biopsy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diffuse large B cell lymphoma (patient information) On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diffuse large B cell lymphoma (patient information)

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diffuse large B cell lymphoma (patient information)

CDC on Diffuse large B cell lymphoma (patient information)

Diffuse large B cell lymphoma (patient information) in the news

Blogs on Diffuse large B cell lymphoma (patient information)

Directions to Hospitals Treating Diffuse large B cell lymphoma

Risk calculators and risk factors for Diffuse large B cell lymphoma (patient information)

Diffuse large B-cell lymphoma (DLBCL or DLBL) is a cancer of B cells, a type of white blood cell responsible for producing antibodies. Diffuse large B cell lymphoma is the most common type of non-Hodgkin lymphoma among adults, with an annual incidence of 78 cases per 100,000 people per year. This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age, though it can also occur in children and young adults in rare cases.

Symptoms of DLBCL

The most common symptoms of diffuse large B cell lymphoma include a rapidly enlarging, non-painful lumps/masses that may be located in neck, groin, or abdomen. The less common symptoms of diffuse large B cell lymphoma include feverweight loss, and drenching night sweats also known as ''B symptoms". Other symptoms might depend on the organ of Involvement for example DLBCL in Chest can lead to shortness of breath or cough while DLBCL involving gut or Stomach can cause Abdominal Pain/ Diarrhea/ Bleeding etc. Involvement of Brain can lead to Headaches, vision or personality changes, seizures etc.

Risk Factors

According to the American Cancer Society, There are several Factors including Old Age, Male Gender, White Ethnicity, Geography, exposure to Certain Drugs and Chemicals, Radiation exposure, and weak Immune System that can increase the chances of getting Non Hodgkin Lymphoma(NHL) among which Diffuse Large B cell Lymphoma is the Most common sub-type. Some Other Risk Factors include hepatitis C virus (HCV) seropositivity, high body mass as a young adult, HIV, and Family History of Lymphoma

Prevention

There are no definitive known causes of DLBCL but preventing risk factors like Immunodeffeciency, radiation exposure, avoiding associated drugs and chemicals can decrease the chances of getting a cancer.

Diagnosis

Diagnostic Work up for Diffuse Large B cell Lymphoma include Laboratory tests including Complete Blood count (CBC), Comprehensive Metabolic Panel, LDH and Uric acid Levels, Genetic testing, molecular diagnostic assays and immunophenotyping. Screening tests for Hepatitis B, Hepatitis C and HIV are usually recommended after diagnosis. Excisional Lymph node or tissue biopsy is diagnostic of diffuse large B cell lymphoma.

When to seek Medical Care

As per American Cancer Society, Symptoms of Lymphoma can vary. It can present early or may not cause any symptoms till late. Below are some of the symptoms that should be concerning and need urgent evaluation by a healthcare professional

Treatment Options

Chemotherapy

Main treatment of Choice for DLBCL. Chemotherapy is administered intravenously and people receiving chemotherapy commonly have a (peripherally inserted central catheter) in their arm near the elbow or a surgically implanted medical port. It is most effective when it is administered multiple times over a period of months (e.g. every 3 weeks, over 6 to 8 cycles). Different regimens of Chemotherapy with different durations/Cycles are used depending on the stage of disease, age of patient and prognsotic index. In general

  • Patients with limited stage disease receive 3 cycles of therapy
  • Patients with extensive disease 6 or 8 cycles of chemotherapy. In the United States, 6 cycles is the preferred approach rather than 8 cycles.

Radiation therapy

Radiation is often added in the treatment. It is used commonly after completing 3 cycles of treatment in limited stage disease. In extensive disease, after 6-8 cycles of chemotherapy, radiation can be used at the end of the treatment to areas of bulky involvement. Radiation therapy alone is not an effective treatment for this disease

Stem Cell Transplantation

High dose Chemotherapy coupled with stem cell transplantation is sometimes used to treat patients whose disease is refractory or relapsed following initial chemotherapy. Most common is Autologous stem cell transplant in which patients receive their own stem cells. Other option is Allogenic stem cell transplant in which patient will receive stem cells from a donor

What to Expect (Prognosis)

The prognosis of diffuse large B cell lymphoma depends on the stage of the disease And International Prognostic Index is widely used to calculate estimated survival. Overall survival for older adults at five years is around 58%[1] while for children with diffuse large B-cell lymphomas, most studies have found 5-year survival rates ranging from about 70% to more than 90%[2]. The Germinal-center sub-type has the best prognosis, with 66.6% of treated patients surviving more than five years.

References

  1. Feugier, P.; Van Hoof, A; Sebban, C; Solal-Celigny, P; Bouabdallah, R; Fermé, C; Christian, B; Lepage, E; Tilly, H; Morschhauser, F; Gaulard, P; Salles, G; Bosly, A; Gisselbrecht, C; Reyes, F; Coiffier, B (2005). "Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte". Journal of Clinical Oncology. 23 (18): 4117–26. PMID 15867204. doi:10.1200/JCO.2005.09.131
  2. http://www.cancer.org/Cancer/Non-HodgkinLymphomainChildren/OverviewGuide/non-hodgkin-lymphoma-in-children-overview-survival-rates


Template:WikiDoc Sources